The Series C Round led by Asahi Glass Co., Ltd. “AGC” includes participation from all prior investors (Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Souther Co.) and new investors Columbia Ventures Corporation and GreenBridge.
“There’s an electricity of discovery here like Genentech and Amgen,” said Dr. Herman. “AbSci’s ability to fold proteins is an innovative art form. This technology enables more efficient manufacturing, which will bring down the price of drugs.”
“The culture here reminds me of Genentech in the early days. It’s an honor to join the team as a Scientific Advisor,” said Dr. Bennett. “AbSci’s technology is a quantum improvement in bacterial expression systems.”
AbSci announced today the appointment of Fred Larimore, PhD to AbSci’s Scientific Advisory Board. Dr. Larimore brings over 30 years of experience in biopharmaceutical manufacturing and process development at leading pharmaceutical companies …